Shares of OrthoPediatrics (KIDS) have gained 2.8% over the past four weeks to close the last trading session at $31.63, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $41.50 indicates a potential upside of 31.2%. The average comprises six short-term price targets ranging from a low of $30 to a high of $50, with a standard deviation of $6.57. While the lowest estimate indicates ...

WARSAW, Ind., Aug. 20, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced plans to host an investor day at 10:30am E.T. on September 12, 2024, in New York, New York. Management's presentation will provide updates on the Company's Specialty Bracing business strategy, product pipeline, and financial outlook and feature a KOL surgeon panel. Investors interested in atte ...

The Celebrated Family-Friendly Resort expands its award-winning Ritz Kids program NAPLES, Fla., Aug. 20, 2024 /PRNewswire/ -- The Ritz-Carlton, Naples announces a new Ritz Kids experience designed to spark curiosity and foster environmental awareness. The recently remastered resort unveiled an expanded Ritz Kids program, featuring a state-of-the-art Ritz Kids Room, resident Naturalist, and destination-specific educational programs, created in partnership with the Conservancy of Southwest Florida. State-of-t ...

Financial Data and Key Metrics - Revenue reached a record $52.8 million in Q2 2024, a 33% increase YoY, surpassing $50 million for the first time in company history [6] - Adjusted EBITDA was $2.6 million in Q2 2024, compared to $2.3 million in Q2 2023 [29] - Gross profit margin increased to 77% in Q2 2024 from 76% in Q2 2023, driven by higher domestic growth and favorable purchase price variance [27] - Total operating expenses increased by $10.9 million (30%) to $46.5 million in Q2 2024, primarily due to the Boston O&P acquisition and increased commission expenses [27] - The company ended Q2 2024 with $30.9 million in cash, short-term investments, and restricted cash [29] Business Line Performance - Global Trauma and Deformity (T&D) revenue grew 37% YoY to $37.8 million in Q2 2024, driven by strong sales of Pega, PNP Tibia, ExFix, and OPSB products [11][12] - Scoliosis revenue increased 26% YoY to $13.7 million in Q2 2024, led by new users of spinal implants and the addition of Boston O&P revenues [16][17] - Specialty Bracing (OPSB) contributed to growth in both T&D and Scoliosis businesses, with the Boston O&P acquisition driving significant synergies [8][15] - International revenue grew 16% YoY to $11.6 million in Q2 2024, primarily driven by T&D products, partially offset by soft Scoliosis revenue [21][25] Market Performance - Domestic revenue in the US grew 39% YoY to $41.2 million in Q2 2024, driven by T&D, Scoliosis, and OPSB businesses [25] - International growth was strong in Europe and Canada, with new accounts opened in Ireland, the UK, Germany, France, and Canada [22] - The company expects strong international growth for Scoliosis in 2024, with stabilization in ordering patterns from South American partners [21] Strategic Direction and Industry Competition - The company is focused on expanding its product portfolio, including new launches like PNP Tibia and DF2, which are expected to drive growth in the coming years [13][14] - The Pediatric Plating Platform (P3) is expected to launch in H1 2025, further strengthening the company's position in pediatric orthopedics [14] - The OPSB business is a key growth driver, with plans for clinic expansion and new product launches contributing to long-term profitability [15][24] - The company is investing in digital health technologies, including 7D and Firefly, which are expected to drive future growth [66][68] Management Commentary on Operating Environment and Future Outlook - The company is operating in a normalized surgical environment, with improved hospital staffing and minimal disruptions to the summer surgery schedule [6] - Management is bullish on the second half of 2024, with robust case schedules and a stable operating environment [7] - The company expects to generate $8-9 million in adjusted EBITDA in 2024 and anticipates a significant step-up in 2025 [9][33] - The company is targeting cash flow breakeven by 2026, with positive adjusted EBITDA expected to offset investments in 2025 [10][33] Other Important Information - The company plans to host an Investor Day in September 2024 to provide more details on growth initiatives, particularly in the OPSB business [24] - The company recently refinanced its credit facility, securing $100 million in capital through a term loan and convertible notes, providing flexibility for future investments [31] - A stock repurchase program of up to $5 million was approved, primarily to manage the strike price of the convertible notes [61] Q&A Session Summary Question: Why was the guidance not raised despite strong performance? - The company maintains a conservative approach to guidance, with organic growth estimated at around 18% after excluding the Boston O&P acquisition [36] - Management remains cautious until Q3 results are finalized, despite a robust summer season [36] Question: What is driving confidence in international Scoliosis growth? - Growth in international Scoliosis is expected to stabilize, with strong demand in markets like Canada and the EU, offsetting volatility in South America [37][38] - The company is managing cash positions by controlling set sales to stocking partners in Latin America [40] Question: What is the outlook for the Boston O&P business? - The Boston O&P business is on track to contribute $25 million annually, with significant opportunities for clinic expansion and integration synergies [43][44] - The company is exploring greenfield locations and small acquisitions to accelerate clinic growth [44] Question: How is the company capitalizing on market disruptions in Scoliosis? - The company is leveraging its exclusive focus on pediatric orthopedics, with new EOS products like RESPONSE Rib and Pelvic system gaining traction in premier children's hospitals [46][47] - The upcoming launch of eLLi and Vertiglide is expected to further strengthen the Scoliosis portfolio [47] Question: What is the approval pathway for the eLLi Growing Rod? - The eLLi Growing Rod is likely to follow a 510(k) pathway, with FDA interactions suggesting a 12-18 month timeline for approval [58][59] - The company does not expect to require post-market clinical data for approval but plans to collaborate with pediatric spine registries to capture data [59] Question: What are the economics of investing in new clinics? - New clinics require an initial investment of approximately $0.5 million, with expected cash flow positivity within 3-4 months [63][64] - The company is confident in the ROI of clinic expansion, given the high demand from hospitals and surgeons [64] Question: What is the outlook for digital health technologies? - The company is seeing strong adoption of 7D and Firefly technologies, with a robust pipeline of placements expected over the next 12-18 months [66][67] - Additional digital health tools are in development, with beta launches expected in the coming months [68] Question: What is driving the conservative guidance for Q3? - The company is cautious due to potential disruptions from RSV and flu season in Q4, which could impact surgical volumes [71][72] - Despite a strong July, management prefers to remain conservative until Q3 results are finalized [71] Question: How will the company achieve EBITDA growth in 2025? - EBITDA growth will be driven by volume leverage, reduced G&A expenses, and higher contribution margins from the OPSB business [74][75] - The company expects adjusted EBITDA to cover set deployment costs in 2025, moving closer to cash flow breakeven in 2026 [75]

WARSAW, Ind., July 22, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS), a company focused exclusively on advancing the field of pediatric orthopedics, today announced that the Company is scheduled to release its second quarter 2024 financial results on Monday, August 5, 2024, after the market closes. OrthoPediatrics will host a conference call on Tuesday, August 6, 2024, at 8:00 a.m. ET to discuss the results. Investor Contact Philip Trip Taylor Gilmartin G ...

Limited-Edition Snapple Fruit Flavor Mix Hitting Shelves This Summer "At SOUR PATCH KIDS, we're always looking for inventive ways to introduce new flavors and spark excitement among our fans," said Grace Howard, Innovation Brand Manager, Mondelēz International. "And what better way to do that than by partnering with Snapple, whose iconic juice drink flavors perfectly complement our sour-then-sweet experience." Learn the Facts for Sweet Rewards* The SOUR PATCH KIDS brand loves to introduce unique flavor comb ...

WARSAW, Ind., June 04, 2024 (GLOBE NEWSWIRE) -- OrthoPediatrics Corp. ("OrthoPediatrics" or the "Company") (Nasdaq: KIDS) a company focused exclusively on advancing the field of pediatric orthopedics, today announced that Dave Bailey, President & Chief Executive Officer is scheduled to participate in a fireside chat at the Truist Securities MedTech Conference, being held in Boston, MA. Event: Truist Securities MedTech Conference Format: Fireside Chat Date: Tuesday, June 18, 2024 Time: 4:45 pm ET An audio we ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______ Commission file number: 001-38242 OrthoPediatrics Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction ...

OrthoPediatrics (KIDS) reported $44.69 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 41.5%. EPS of -$0.30 for the same period compares to -$0.29 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $41.63 million, representing a surprise of +7.35%. The company delivered an EPS surprise of +28.57%, with the consensus EPS estimate being -$0.42.While investors scrutinize revenue and earnings changes year-over-year and how they compare with ...

OrthoPediatrics (KIDS) came out with a quarterly loss of $0.30 per share versus the Zacks Consensus Estimate of a loss of $0.42. This compares to loss of $0.29 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 28.57%. A quarter ago, it was expected that this maker of orthopedic devices would post a loss of $0.28 per share when it actually produced a loss of $0.23, delivering a surprise of 17.86%.Over the last four quarters, the ...